Register for our free email digests:
Clinical / R&D
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Research & Development
NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas Merck's Keytruda succeeded, but some analysts aren't so sure.
Testifying before Senate subcommittee, FDA commissioner put his plans for facilitating new drug development front and center, a shift from his many past discussions about generic drug development.
Using lessons learned from the first wave of biosimilar approvals – and citing high prices in the US – some developers are starting to 'think small' with biosimilars for rare disease markets. Alexion’s Soliris is a case in point.
US agency will be more 'proactive' in engaging with outside groups interested in using the biomarker qualification process using the new resources and directives of the 21st Century Cures Act and the pending Prescription Drug User Fee Act reauthorization.
An opinion from a European Commission committee on using non-human primates in pharmaceutical research is being criticized as a missed opportunity that wastes time in developing new models of biomedical research.
Work To Replace, Reduce And Refine But Use Of Non-Human Primates In Research Still Necessary, Says EU Panel
Non-human primates will have to continue to be used in biomedical research for the foreseeable future, according to the European Commission’s Scientific Committee on Health Environmental and Emerging Risks. A ban would stall scientific progress but work should continue under the replacing, reducing and refining approach, the panel says.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.